Kindred Biosciences (NASDAQ:KIN) Receives “Hold” Rating from BMO Capital Markets

Retrieved on: 2018-01-01 01:26:15

Tags for this article:

Business

Economy

Click the tags to see associated articles and topics

Kindred Biosciences (NASDAQ:KIN) Receives “Hold” Rating from BMO Capital Markets. View article details on hiswai:

Excerpt

<div><b>Vanguard Group</b> Inc. grew its holdings in Kindred Biosciences by 57.7% during the second quarter. <b>Vanguard Group</b> Inc. now owns 745,322 shares of the biopharmaceutical company's stock valued at $6,410,000 after purchasing an additional 272,612 shares during the period. State Street Corp bought ...</div>

Article found on:

View Original Article